Biopharm company Cellceutix today said the U.S. Food and Drug Administration (FDA) has reviewed the company’s Investigational New Drug (IND) application for its novel anti-cancer compound Kevetrin™ and has approved the company’s advancement to phase I clinical trial.
The phase 1 clinical trial for Kevetrin will take place at Harvard Cancer Center’s Dana-Farber Cancer Institute and partner Beth Israel Deaconess Medical Center.
The company also announced that both the Institutional Review Board and the Scientific Review Committee have approved the protocol for the clinical trial.
Cellceutix said it will provide details on the commencement of the clinical trials to shareholders next week.
Cellceutix is focused on the discovery of small molecule drugs to treat unmet medical conditions, including drug-resistant cancers and autoimmune diseases. In addition to its flagship compound Kevetrin, the company owns the rights to seven other drug compounds, including KM-133 in development for psoriasis, and KM-391 for the treatment of the core symptoms of autism.
For more information visit www.cellceutix.com
Let us hear your thoughts below:
